Open AccessSex Differences in Clinical and Genetic Determinants of Levodopa Peak-Dose Dyskinesias in Parkinson Disease
Author(s) -
Mario Zappia,
Grazia Annesi,
Giuseppe Nicoletti,
Gennarina Arabia,
Ferdinanda Annesi,
Demetrio Messina,
Pierfrancesco Pugliese,
Patrizia Spadafora,
Patrizia Tarantino,
Sara Carrideo,
Donatella Civitelli,
Elvira Valeria De Marco,
Innocenza C. Cirò-Candiano,
Antonio Gambardella,
Aldo Quattrone
Publication year - 2005
Publication title -
archives of neurology
Language(s) - English
Resource type - Journals
eISSN - 1538-3687
pISSN - 0003-9942
DOI - 10.1001/archneur.62.4.601
Subject(s) - levodopa , parkinson's disease , odds ratio , medicine , disease , population , confidence interval , logistic regression , oncology , pediatrics , psychology , environmental health
Several factors, both clinical and genetic, may account for the risk of developing levodopa-induced peak-dose dyskinesias (PDD) in patients with Parkinson disease, but it is unclear how these factors interact for modulating the individual susceptibility for PDD.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom